The B-cell response to a primary and booster course of MenACWY-CRM197 vaccine administered at 2, 4 and 12 months of age
A quadrivalent meningococcal vaccine conjugated to CRM197 (MenACWY-CRM197) is immunogenic in young infants. We assessed the memory B-cell and antibody responses after a primary and booster course of MenACWY-CRM197 in children. At 5 months of age, following primary immunisation, serogroup-specific me...
| Egile Nagusiak: | , , , , , , , , , |
|---|---|
| Formatua: | Journal article |
| Hizkuntza: | English |
| Argitaratua: |
2013
|
| _version_ | 1826270139298873344 |
|---|---|
| author | Blanchard-Rohner, G Snape, MD Kelly, D O'Connor, D John, T Clutterbuck, E Ohene-Kena, B Klinger, C Odrljin, T Pollard, A |
| author_facet | Blanchard-Rohner, G Snape, MD Kelly, D O'Connor, D John, T Clutterbuck, E Ohene-Kena, B Klinger, C Odrljin, T Pollard, A |
| author_sort | Blanchard-Rohner, G |
| collection | OXFORD |
| description | A quadrivalent meningococcal vaccine conjugated to CRM197 (MenACWY-CRM197) is immunogenic in young infants. We assessed the memory B-cell and antibody responses after a primary and booster course of MenACWY-CRM197 in children. At 5 months of age, following primary immunisation, serogroup-specific memory B-cells were detectable in fewer than 25% of children, although protective antibody titres (hSBA≥4) were detectable in 69% of children against serogroup A and more than 95% against the other serogroups. At 12 months, before booster immunisation the percentages with hSBA≥4 were 5% for serogroup A, and between 44 and 70% for the other serogroups. One month after booster immunisation with MenACWY-CRM197 over 50% of children had detectable memory B-cells, and 91% had hSBA≥4 against serogroup A and more than 99% against the other serogroups. These data show that few antigen-specific anticapsular memory B-cells can be detected after two-doses priming with MenACWY-CRM197. For MenC and CRM197, the antigens with the highest number of B-cells at 5 months, there was a definite (p≤0.02) but weak correlation with antibody persistence at 12 months. Although previous studies suggest that measuring memory B-cell responses after priming immunisations in infancy can be used to predict antibody persistence and memory responses, this may not be suitable for all antigens in young children. © 2013 Elsevier Ltd. |
| first_indexed | 2024-03-06T21:36:09Z |
| format | Journal article |
| id | oxford-uuid:46566ed4-1ffb-4e08-b66f-d112a14ef43d |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T21:36:09Z |
| publishDate | 2013 |
| record_format | dspace |
| spelling | oxford-uuid:46566ed4-1ffb-4e08-b66f-d112a14ef43d2022-03-26T15:13:06ZThe B-cell response to a primary and booster course of MenACWY-CRM197 vaccine administered at 2, 4 and 12 months of ageJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:46566ed4-1ffb-4e08-b66f-d112a14ef43dEnglishSymplectic Elements at Oxford2013Blanchard-Rohner, GSnape, MDKelly, DO'Connor, DJohn, TClutterbuck, EOhene-Kena, BKlinger, COdrljin, TPollard, AA quadrivalent meningococcal vaccine conjugated to CRM197 (MenACWY-CRM197) is immunogenic in young infants. We assessed the memory B-cell and antibody responses after a primary and booster course of MenACWY-CRM197 in children. At 5 months of age, following primary immunisation, serogroup-specific memory B-cells were detectable in fewer than 25% of children, although protective antibody titres (hSBA≥4) were detectable in 69% of children against serogroup A and more than 95% against the other serogroups. At 12 months, before booster immunisation the percentages with hSBA≥4 were 5% for serogroup A, and between 44 and 70% for the other serogroups. One month after booster immunisation with MenACWY-CRM197 over 50% of children had detectable memory B-cells, and 91% had hSBA≥4 against serogroup A and more than 99% against the other serogroups. These data show that few antigen-specific anticapsular memory B-cells can be detected after two-doses priming with MenACWY-CRM197. For MenC and CRM197, the antigens with the highest number of B-cells at 5 months, there was a definite (p≤0.02) but weak correlation with antibody persistence at 12 months. Although previous studies suggest that measuring memory B-cell responses after priming immunisations in infancy can be used to predict antibody persistence and memory responses, this may not be suitable for all antigens in young children. © 2013 Elsevier Ltd. |
| spellingShingle | Blanchard-Rohner, G Snape, MD Kelly, D O'Connor, D John, T Clutterbuck, E Ohene-Kena, B Klinger, C Odrljin, T Pollard, A The B-cell response to a primary and booster course of MenACWY-CRM197 vaccine administered at 2, 4 and 12 months of age |
| title | The B-cell response to a primary and booster course of MenACWY-CRM197 vaccine administered at 2, 4 and 12 months of age |
| title_full | The B-cell response to a primary and booster course of MenACWY-CRM197 vaccine administered at 2, 4 and 12 months of age |
| title_fullStr | The B-cell response to a primary and booster course of MenACWY-CRM197 vaccine administered at 2, 4 and 12 months of age |
| title_full_unstemmed | The B-cell response to a primary and booster course of MenACWY-CRM197 vaccine administered at 2, 4 and 12 months of age |
| title_short | The B-cell response to a primary and booster course of MenACWY-CRM197 vaccine administered at 2, 4 and 12 months of age |
| title_sort | b cell response to a primary and booster course of menacwy crm197 vaccine administered at 2 4 and 12 months of age |
| work_keys_str_mv | AT blanchardrohnerg thebcellresponsetoaprimaryandboostercourseofmenacwycrm197vaccineadministeredat24and12monthsofage AT snapemd thebcellresponsetoaprimaryandboostercourseofmenacwycrm197vaccineadministeredat24and12monthsofage AT kellyd thebcellresponsetoaprimaryandboostercourseofmenacwycrm197vaccineadministeredat24and12monthsofage AT oconnord thebcellresponsetoaprimaryandboostercourseofmenacwycrm197vaccineadministeredat24and12monthsofage AT johnt thebcellresponsetoaprimaryandboostercourseofmenacwycrm197vaccineadministeredat24and12monthsofage AT clutterbucke thebcellresponsetoaprimaryandboostercourseofmenacwycrm197vaccineadministeredat24and12monthsofage AT ohenekenab thebcellresponsetoaprimaryandboostercourseofmenacwycrm197vaccineadministeredat24and12monthsofage AT klingerc thebcellresponsetoaprimaryandboostercourseofmenacwycrm197vaccineadministeredat24and12monthsofage AT odrljint thebcellresponsetoaprimaryandboostercourseofmenacwycrm197vaccineadministeredat24and12monthsofage AT pollarda thebcellresponsetoaprimaryandboostercourseofmenacwycrm197vaccineadministeredat24and12monthsofage AT blanchardrohnerg bcellresponsetoaprimaryandboostercourseofmenacwycrm197vaccineadministeredat24and12monthsofage AT snapemd bcellresponsetoaprimaryandboostercourseofmenacwycrm197vaccineadministeredat24and12monthsofage AT kellyd bcellresponsetoaprimaryandboostercourseofmenacwycrm197vaccineadministeredat24and12monthsofage AT oconnord bcellresponsetoaprimaryandboostercourseofmenacwycrm197vaccineadministeredat24and12monthsofage AT johnt bcellresponsetoaprimaryandboostercourseofmenacwycrm197vaccineadministeredat24and12monthsofage AT clutterbucke bcellresponsetoaprimaryandboostercourseofmenacwycrm197vaccineadministeredat24and12monthsofage AT ohenekenab bcellresponsetoaprimaryandboostercourseofmenacwycrm197vaccineadministeredat24and12monthsofage AT klingerc bcellresponsetoaprimaryandboostercourseofmenacwycrm197vaccineadministeredat24and12monthsofage AT odrljint bcellresponsetoaprimaryandboostercourseofmenacwycrm197vaccineadministeredat24and12monthsofage AT pollarda bcellresponsetoaprimaryandboostercourseofmenacwycrm197vaccineadministeredat24and12monthsofage |